Omeros Corporation (OMER)
NASDAQ • Healthcare
Last close at September 9, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Omeros Corporation keeps $46 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 12
in 63 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
About Omeros Corporation
Omeros Corporation is an OMER-listed Biotechnology company on NASDAQ that develops small-molecule and protein-based therapies. The company focuses on inflammatory conditions, complement-mediated diseases, immune-related cancers, and addiction or compulsion disorders, and it is a drug developer founded in 1994 and based in Seattle, Washington.
Today's Snapshot
OMER opened 1.4% lower at 19.12, while its sector was flat. The session opened with OMER within 4.2% of its 52-week high of 19.65.
Trading Volume
Below 10d avg (1.2M)
285.8K
vs S&P 500 Today
Underperforming Market
-2.21%
Updated: September 10, 2026 at 14:37 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$11.94 - $18.83Buy
- RSI (14)64.78Neutral
- Stochastic %K (14, 3, 3)70.10Neutral
- MACD Level (12, 26)1.41Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.